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Q34	 - Naloxone	 Encourages	Addictive	 Opioid	 Misuse?
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Q34	–	Question	34	shows	significant	overall	disagreement	with	the	idea	that	Naloxone	
encourages	patients	to	use	opioids	in	an	addictive	manner.	A	total	of	80	respondents	(78%)	
either	disagreed	or	strongly	disagreed	with	the	statement;	another	20	(19%)	were	neutral	
responses,	and	there	were	only	3	agreements.	Most	of	the	strong	disagreements	were	found	in	
Anesthesiology,	Internal	Medicine,	Psychiatry,	and	Surgery,	as	well	as	Radiology.	
	
Q35	–	The	final	question,	on	whether	Naloxone	actually	enables	drug	use,	had	an	even	stronger	
disagreement	response	than	the	previous	question.	A	total	of	88	respondents	(85%)	either	
disagreed	or	strongly	disagreed	with	the	statement,	solidly	rejecting	the	enabling	view.	The	
remaining	15%	were	all	neutral	responses;	there	were	no	agreements.	The	largest	rate	of	
neutral	responses	were	found	in	Surgery	(30%),	and	Anesthesiology	(21%).	Especially	high	rates	
of	strong	disagreement	(>60%	of	program	respondents)	within	the	larger	groups	were	found	in	
Internal	Medicine,	IM-Pediatrics,	and	Pediatrics,	as	well	as	in	Radiology	and	Radiation	Oncology.	
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Conclusion	
	
As	noted	in	the	Introduction,	the	purpose	of	this	study	was	to	ascertain	the	attitudes	of	
residents	towards	Naloxone	and	their	prescription	practices,	as	well	as	analyze	if	there	were	
specific	differences	between	residencies	on	these	topics.	Given	that	the	number	of	respondents	
was	103	out	of	735	residents	(14%),	it	is	difficult	to	draw	definitive	conclusions	regarding	
individual	residency	programs	(especially	for	those	which	had	5	or	fewer	residents	responding).	
However,	despite	this	limitation	some	conclusions	can	be	gathered,	certainly	within	the	
confines	of	the	responses	received.	
	
It	is	true	that	many	of	the	differences	cited	between	residency	responses	for	the	larger	groups	
can	likely	be	explained	by	differences	in	patient	populations	and	the	medical	services	provided	
by	different	programs.	Nevertheless,	observed	differences	in	terms	of	knowledge,	training,	
comfort,	and	experience	concerning	Naloxone	administration	and	prescribing,	may	also	suggest	
areas	or	targets	for	additional	attention	or	educational	interventions.	
	
The	first	part	of	the	study,	focused	on	prescription	practices	of	residents,	showed	that	slightly	
more	than	half	of	the	respondents	have	been	trained	to	use	Naloxone	in	an	overdose	situation,	
but	less	than	half	in	how	to	prescribe	it.	Still	fewer	have	actually	administered	or	prescribed	
Naloxone.	This	despite	having	many	of	their	patients	struggling	with	opioids	and	in	need	of	
overdose	prevention	measures.	
	
A	similar	pattern	was	seen	in	the	second	part	of	the	study,	concerning	the	resident	attitudes	
toward	Naloxone,	where	across	the	board	residents	had	a	favorable	opinion	toward	Naloxone,	
but	were	unfamiliar	or	uncomfortable	prescribing	it	to	their	patients.	Nearly	all	(95%)	of	
respondents	view	Naloxone	as	a	potential	lifesaving	intervention,	but	only	half	feel	comfortable	
administering	it,	or	feel	knowledgeable	about	it.	There	is	very	strong	agreement	that	Naloxone	
does	not	encourage	addictive	opioid	misuse	and	does	not	enable	drug	use,	and	likewise	that	it	
should	be	available	to	all	patients	(not	just	opioid	patients),	as	well	as	to	friends	and	family	
members—and	that	Naloxone	is	not	currently	easy	for	patients	to	obtain.	Yet,	when	asked	if	
they	have	the	knowledge	to	explain	Naloxone	use,	and	feel	comfortable	doing	so,	we	see	that	
70-75%	say	no	or	equivocate,	and	over	half	do	not	feel	comfortable	prescribing	Naloxone.	
Perhaps	most	important,	70%	do	not	feel	they	can	confidently	identify	patients	who	would	
benefit	from	being	prescribed	Naloxone.	Surely	it	is	possible	to	do	better	than	this.	
	
Recently,	the	AMA	Opioid	Task	Force	issued	updated	guidance	“encouraging	physicians	to	
consider	co-prescribing	Naloxone	when	clinically	appropriate	for	patients	who	are	at	risk	for	
opioid	overdose	or	might	be	able	to	help	someone	at	risk.”	In	the	same	article,	Dr.	Sarah	
Wakeman	states	“co-prescribing	Naloxone	is	important	to	ensure	all	people	being	prescribed	
opioids	at	risk	for	overdose	have	this	lifesaving	medication	at	home,	similar	to	how	we	might	
think	about	co-prescribing	glucagon	to	someone	with	insulin-dependent	diabetes”	(9).		
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Thus,	given	the	scope	of	opioid-related	deaths	in	this	country,	it	is	essential	that	the	residents	
of	the	University	of	Michigan	Medical	School	of	all	disciplines	be	exposed	to	Naloxone	
education	and	feel	comfortable	prescribing	it	when	necessary.	Indeed,	a	study	just	performed	
in	2018	showed	that	a	brief	curricular	intervention	among	medical	residents	at	an	urban,	
tertiary	medical	center	improved	their	knowledge,	attitudes,	and	comfort	levels	toward	
Naloxone,	and	significantly	increased	their	prescribing	rates	(12).	This	type	of	approach	should	
be	given	consideration	at	UMMS.	
	
	
In	closing,	I	wish	to	thank	Dr.	Jouney	for	his	advice	and	assistance	throughout	the	project	and	
Dr.	Jibson	for	his	help	and	guidance.	I	am	also	grateful	to	all	residency	program	directors	for	
their	support	as	well	as	to	the	residents	who	took	the	time	to	complete	the	survey.	
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